scholarly article | Q13442814 |
P50 | author | André Reis | Q522465 |
Matthias W. Beckmann | Q72940290 | ||
Arndt Hartmann | Q89782316 | ||
Michael P. Lux | Q37372079 | ||
Peter A. Fasching | Q64005064 | ||
Arif B. Ekici | Q64409983 | ||
P2093 | author name string | Alexander Hein | |
Claudia Rauh | |||
Rüdiger Schulz-Wendtland | |||
Sebastian M Jud | |||
Cornelia Kraus | |||
Juliane Hoyer | |||
Lothar Häberle | |||
Naiba Nabieva | |||
Ramona Erber | |||
Georgia Vasileiou | |||
Carolin C Hack | |||
Marius Wunderle | |||
Gregor Olmes | |||
P2860 | cites work | Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations | Q78299914 |
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients | Q80122576 | ||
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consorti | Q86554647 | ||
Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe | Q87935958 | ||
Genome-wide association studies identify four ER negative-specific breast cancer risk loci | Q24622610 | ||
Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 | ||
Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO | Q26995389 | ||
Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study | Q28075560 | ||
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer | Q28303909 | ||
Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. | Q30238753 | ||
Determination of interval cancer rates in the German mammography screening program using population-based cancer registry data | Q30719843 | ||
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer | Q33566957 | ||
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification | Q33591915 | ||
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival | Q33828680 | ||
Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population | Q33892384 | ||
Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions | Q34038964 | ||
Performance of common genetic variants in breast-cancer risk models | Q34064069 | ||
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). | Q34085748 | ||
Genome-wide association study identifies five new breast cancer susceptibility loci | Q34114293 | ||
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information | Q34267477 | ||
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 | Q34384153 | ||
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer | Q34631785 | ||
Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer | Q34736112 | ||
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results | Q34788325 | ||
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors | Q34898735 | ||
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer | Q34996647 | ||
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen | Q35006860 | ||
Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk | Q35061252 | ||
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population | Q35089479 | ||
Model for individualized prediction of breast cancer risk after a benign breast biopsy | Q35144259 | ||
Lifetime cancer risks in individuals with germline PTEN mutations. | Q35681689 | ||
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures | Q35752042 | ||
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer | Q35755874 | ||
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients | Q35781316 | ||
Common germline polymorphisms associated with breast cancer-specific survival | Q35794653 | ||
19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density | Q35957063 | ||
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
Identification of novel genetic markers of breast cancer survival | Q36014067 | ||
The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
The role of genetic breast cancer susceptibility variants as prognostic factors | Q36142060 | ||
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort | Q36336239 | ||
Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement | Q36393193 | ||
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. | Q36435849 | ||
The incidence of interval cancers in the German mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia | Q36446560 | ||
SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival | Q36545934 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk | Q36600605 | ||
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial | Q36634556 | ||
iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management | Q36678510 | ||
The BOADICEA model of genetic susceptibility to breast and ovarian cancer | Q36695832 | ||
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors | Q36720821 | ||
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers | Q36742577 | ||
Genome-wide association analysis identifies three new breast cancer susceptibility loci | Q36842233 | ||
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Q36897003 | ||
Comparison of Clinical and Automated Breast Density Measurements: Implications for Risk Prediction and Supplemental Screening | Q36950678 | ||
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. | Q37300024 | ||
Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium | Q37307937 | ||
Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older | Q37353842 | ||
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. | Q37356243 | ||
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. | Q37369631 | ||
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model | Q37378034 | ||
Mammography Screening - as of 2013. | Q37389694 | ||
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface | Q37507410 | ||
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations | Q37524058 | ||
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers | Q37578078 | ||
High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations | Q37669153 | ||
A clinical model for identifying the short-term risk of breast cancer | Q37697979 | ||
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes | Q38613552 | ||
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | Q38717239 | ||
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study | Q39006292 | ||
Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography | Q39622978 | ||
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer | Q39958494 | ||
Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium | Q40137431 | ||
A Standard Mammography Unit - Standard 3D Ultrasound Probe Fusion Prototype: First Results | Q40486932 | ||
Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods | Q41011976 | ||
Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound | Q41570633 | ||
Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond | Q41579926 | ||
Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients | Q42013702 | ||
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity | Q45746480 | ||
Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Q46103372 | ||
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study | Q46721561 | ||
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium | Q47190168 | ||
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study | Q47552886 | ||
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. | Q48717652 | ||
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? | Q50033721 | ||
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. | Q51764547 | ||
A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 | ||
[Future of mammography-based imaging]. | Q53077783 | ||
A common coding variant in CASP8 is associated with breast cancer risk | Q57250674 | ||
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer | Q57251792 | ||
The calculation of breast cancer risk for women with a first degree family history of ovarian cancer | Q72397549 | ||
Validation studies on a model for breast cancer risk | Q72412463 | ||
P433 | issue | 5 | |
P304 | page(s) | 481-492 | |
P577 | publication date | 2018-05-01 | |
P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
P1476 | title | Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. | |
P478 | volume | 78 |
Q90107270 | Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy |
Q90285490 | Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study |
Q92103705 | Epithelial ovarian cancer risk: A review of the current genetic landscape |
Q90219103 | Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients |
Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
Q98514326 | Supervariants identification for breast cancer |
Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
Q59335362 | Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer |
Q64102998 | Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer |
Q64102991 | Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice |
Q90092211 | Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies |
Q58587476 | [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes] |
Search more.